Ozempic and Zepbound are both prescription injections that are part of the GLP-1 drug class. They have different active ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

Many people stop taking GLP-1 drugs like Ozempic within a year, but doing so often leads to weight regain. Here's what to know before stopping.

From supplements to injectables to belly-fat blasting beverages, there are plenty of products that claim to speed weight loss ...

Eli Lilly is tagging along on actress Kym Whitley’s blockbuster summer in a fresh Zepbound partnership with the “Happy ...

After watching her weight go up and down throughout her career, Whitley was recommended the injectable prescription medicine ...

Private equity sees attractive demand and growth opportunities within the fragmented healthcare cost containment service ...

When nurse practitioner Amy Rabon launched Sisterhood Sanctuary’s weight management program in 2019, 25 people signed up, ...

Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...

A new study in mice shows that tirzepatide—the active ingredient in the popular drugs Mounjaro and Zepbound—not only helps shed pounds but may also slow or reduce the growth of breast cancer tumors ...

By embedding machine learning into the core of pricing infrastructure, organizations can shift from reactive to proactive.

Market OutlineThe Global Weight Loss Drugs Market is valued at USD 2.88 Billion in 2024 and is projected to reach a value ...